Fig. 3

p66ShcA is required for efficient triple-negative breast cancer lung metastasis. a Mammary fat pad (MFP) injection of parental, p66-CR (VC), p66-CR (WT), and p66-CR (S36A) expressing lung-metastatic 4T1 cells (537 population). The data is shown as average tumor volume (mm³) ± SEM (n = 18 tumors/group). b Percentage of mice with lung metastases following primary tumor resection. Mice were sacrificed 21 days post-resection of the primary tumor. Statistical analysis was performed using a Fisher’s exact test (**P < 0.01). c Metastatic burden, following primary tumor resection, in the lungs of mice bearing the indicated 537 breast cancer cell populations. The data is shown as average lung tumor burden ±SEM (parental: n = 17; p66-CR (VC): n = 18; p66-CR (WT): n = 18; p66-CR (S36A): n = 13). Representative H&E images are shown. d Metastatic burden in the lungs of mice following tail vein injection of the indicated 537 lung-metastatic breast cancer cells. All mice were necropsied 21 days post-injection. The data is shown as average lung tumor burden ±SEM (n = 7 mice per cohort). Representative H&E images are shown. e Metastatic burden in the lungs of mice following tail vein injection of the indicated 537 lung-metastatic breast cancer cells. Mice bearing parental 537 cells were necropsied 21 days post-injection, whereas the remaining mice were necropsied 26 days post-injection. Representative H&E images are shown. The data is shown as average lung tumor burden ±SEM (n = 13 mice per cohort). For panel b, statistical analysis was performed using a Fisher’s exact test (**P < 0.01). For panels c–e, statistical analysis was performed using a one-way ANOVA with a Tukey’s multiple comparison test (*P < 0.05; **P < 0.01; ***P < 0.001)